AMG 747 / Amgen - LARVOL DELTA

Non-Dopaminergic Mechanisms and Negative Symptoms in Schizophrenia: Opportunities for Repurposing? (EPA 2019) - "...Results - Five major compounds that had cognition and negative symptoms as main targets, were abandoned, four failed to provide significant superiority over placebo (encenicline, TC-5619, bitopertin, pomaglumetad methionil) and one was withdrawn due to safety concerns (AMG 747)...These include MIN-101, a novel cyclic amido derivative, cariprazine, a D2 and D3 receptor partial agonist, with high selectivity towards the D3 receptor, minocycline, a broad-spectrum tetracyclic antibiotic displaying neuroprotective properties, and raloxifene, a selective estrogen receptor modulator for post-menopausal women...Favorable Results of psychosocial approaches will also be discussed. Discussion-The Conclusions from almost a decade ago of Patient Outcomes Research Team schizophrenia guidelines, that no treatment for negative symptoms has proven to have enough evidence to support a treatment recommendation, remain intact."